Pipeline Review of Opioid-Induced Constipation (OIC) Report Analysis 2023

Posted by Deeksha on October 1st, 2019

The global market status for Opioid-Induced Constipation (OIC) is precisely examined through a smart research report added to the broad database managed by Market Research Hub (MRH). This study is titled “Opioid-Induced Constipation (OIC)-Pipeline Review, H2 2019”, which tends to deliver in-depth knowledge associated to the Opioid-Induced Constipation (OIC) market for the present and forecasted period 2019. Furthermore, the report examines the target market based on market size, revenue and geography; making it quite useful for the readers.

Get Sample Copy@ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2519476

Opioid-Induced Constipation (OIC) - Pipeline Review, H2 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Opioid-Induced Constipation (OIC) - Pipeline Review, H2 2019, provides an overview of the Opioid-Induced Constipation (OIC) (Toxicology) pipeline landscape.

Opioids are effective pain relievers, but often have the side effect of constipation. These medicines affect the gastrointestinal tract in a variety of ways. Opioids increase the amount of time it takes stool to move through the gastric system. They increase non-propulsive contractions in the middle of the small intestine (jejunum) and decrease longitudinal propulsive peristalsis - motions critical to moving food through the intestines. This results in food that fails to travel through the digestive tract. Opioids are also able to partially paralyze the stomach (gastroparesis) so that food remains in the digestive organ for a longer period of time. Additionally opioids reduce digestive secretions and decrease the urge to defecate. Symptoms of OIC include feeling and being sick, tiredness and lethargy, appetite loss, feeling depressed.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Opioid-Induced Constipation (OIC) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Opioid-Induced Constipation (OIC) (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Opioid-Induced Constipation (OIC) (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Opioid-Induced Constipation (OIC) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Phase I stages are 2, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Opioid-Induced Constipation (OIC) (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Opioid-Induced Constipation (OIC) (Toxicology).
- The pipeline guide reviews pipeline therapeutics for Opioid-Induced Constipation (OIC) (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Opioid-Induced Constipation (OIC) (Toxicology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Opioid-Induced Constipation (OIC) (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Opioid-Induced Constipation (OIC) (Toxicology)

Request TOC of the Report @ https://www.marketresearchhub.com/report/opioid-induced-constipation-oic-pipeline-review-h2-2019-report.html

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Opioid-Induced Constipation (OIC) - Overview
Opioid-Induced Constipation (OIC) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Opioid-Induced Constipation (OIC) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Opioid-Induced Constipation (OIC) - Companies Involved in Therapeutics Development
Bausch Health Companies Inc
Mallinckrodt Plc
Shionogi & Co Ltd
Opioid-Induced Constipation (OIC) - Drug Profiles
dolcanatide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lubiprostone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naldemedine tosylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naloxone hydrochloride PR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize Mu Opioid Receptor for Drug Abuse, Alcohol Addiction and OIC - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Opioid-Induced Constipation (OIC) - Dormant Projects
Opioid-Induced Constipation (OIC) - Discontinued Products
Opioid-Induced Constipation (OIC) - Product Development Milestones
Featured News & Press Releases
Aug 28, 2019: BioDelivery Sciences announces presentation on Symproic at PAINWeek 2019 National Conference on Pain Management
Feb 22, 2019: Shionogi receives European Union Marketing Authorisation for Rizmoic (naldemedine) for the treatment of opioid-induced constipation in adults previously treated with a laxative
Dec 18, 2018: Shionogi receives positive opinion for Rizmoic in latest announcement from the Committee for Medicinal Products for Human Use (CHMP)
Dec 13, 2018: Rizmoic (naldemedine) received a positive opinion for the treatment of opioid-induced constipation
Sep 04, 2018: Shionogi announces upcoming presentations from Symproic (naldemedine) studies at PAINWeek 2018 Annual Conference